Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 576 to 600 of 881

TitleReference numberPublishedLast updated
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the kneeTA508
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerTA509
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis CTA507
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal womenTA160
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal womenTA161
Pirfenidone for treating idiopathic pulmonary fibrosisTA504
Intrabeam radiotherapy system for adjuvant treatment of early breast cancerTA501
Ibrutinib for treating relapsed or refractory mantle cell lymphomaTA502
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Lenvatinib with everolimus for previously treated advanced renal cell carcinomaTA498
Glecaprevir–pibrentasvir for treating chronic hepatitis CTA499
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Golimumab for treating active non-radiographic axial spondyloarthritisTA497
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478

Results per page

  1. 10
  2. 25
  3. 50
  4. All